New advances in beta-blocker therapy in heart failure
Vincenzo Barrese1, Maurizio Taglialatela
1Section of Pharmacology, Department of Neuroscience, University of Naples Federico II Naples, Italy.
Frontiers in Physiology
|December 3, 2013
Summary
Beta-blockers (BB) are now recognized as effective treatments for heart failure (HF), despite initial concerns. Research indicates BBs manage HF by counteracting harmful sympathetic nervous system activation and inflammation.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Historically, beta-blockers (BB) were contraindicated in heart failure (HF) due to negative inotropic effects.
- Emerging evidence suggests HF involves neuro-hormonal activation and inflammation, mechanisms potentially targeted by BBs.
- Sympathetic nervous system overactivation in HF increases myocardial oxygen demand, ischemia, and oxidative stress, worsening cardiac function.
Purpose of the Study:
- To review the pharmacological properties and classification of beta-blockers (BB).
- To explore the rationale for BB use in heart failure (HF) based on adrenergic system alterations.
- To discuss the molecular mechanisms, including genetic factors, influencing BB efficacy in HF patients.
Main Methods:
- Review of clinical trial evidence on beta-blocker (BB) efficacy in heart failure (HF).
- Analysis of pharmacological differences among BBs regarding receptor selectivity and additional effects.
- Examination of the role of the adrenergic system and molecular mechanisms in HF pathogenesis and BB response.
Main Results:
- Numerous clinical trials have established beta-blockers (BB) as effective therapeutic agents for heart failure (HF).
- BBs are now included in heart failure (HF) treatment guidelines due to their proven benefits.
- Controversies persist regarding specific BB selection, patient heterogeneity, and response variability.
Conclusions:
- Beta-blockers (BB) are crucial in managing heart failure (HF) by mitigating sympathetic overactivity.
- Understanding BB pharmacology and molecular mechanisms is essential for optimizing HF treatment.
- Further research is needed to address the heterogeneity in BB response and guide personalized therapy.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
2.9K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:30Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
01:22Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635